Food effects have been evaluated for other novel FLT3 inhibitors: gilteritinib, which is approved for adults with relapsed or refractory AML with FLT3 mutation, and crenolanib, which is currently in phase 3 evaluation. Here, FLT3 is linked to acute myeloid leukemia.